PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

INTRODUCTION: [(177)Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy is only achieved in approximately half of patients. It is clinically important to identify patients at risk of poor outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Seifert, Robert, Kessel, Katharina, Schlack, Katrin, Weber, Manuel, Herrmann, Ken, Spanke, Maximilian, Fendler, Wolfgang P., Hadaschik, Boris, Kleesiek, Jens, Schäfers, Michael, Weckesser, Matthias, Boegemann, Martin, Rahbar, Kambiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041668/
https://www.ncbi.nlm.nih.gov/pubmed/32970216
http://dx.doi.org/10.1007/s00259-020-05040-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041668/
https://www.ncbi.nlm.nih.gov/pubmed/32970216
http://dx.doi.org/10.1007/s00259-020-05040-1

Ejemplares similares